XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
XORTX Therapeutics announced the acceptance of their abstract at the American Society of Nephrology, focusing on xanthine oxidase in polycystic kidney disease. The study, conducted at the University of Colorado and sponsored by XORTX, revealed significant findings in both rat and mouse PKD models. Key results showed that increased uric acid led to increased cyst growth, while xanthine oxidase inhibitor decreased serum uric acid and cyst growth. Clinical results from the Halt Clinical Trial - Group A demonstrated that patients with elevated serum uric acid experienced increased total kidney volume and faster PKD progression. Additionally, increased serum XO activity was linked to earlier onset of high blood pressure.
XORTX Therapeutics ha annunciato l'accettazione del proprio abstract presso l'American Society of Nephrology, incentrato su l'ossidasi della xantina nella malattia policistica renale. Lo studio, condotto presso l'Università del Colorado e sponsorizzato da XORTX, ha rivelato risultati significativi sia nei modelli di PKD su ratto che su topo. I risultati chiave hanno mostrato che un aumento dell'acido urico ha portato a una crescita maggiore delle cisti, mentre l'inibitore dell'ossidasi della xantina ha ridotto l'acido urico sierico e la crescita delle cisti. I risultati clinici del Halt Clinical Trial - Gruppo A hanno dimostrato che i pazienti con acido urico sierico elevato hanno mostrato un aumento del volume totale dei reni e una progressione più rapida della PKD. Inoltre, un aumento dell'attività dell'XO sierico è stato collegato all'insorgenza anticipata dell'ipertensione.
XORTX Therapeutics anunció la aceptación de su resumen en la Sociedad Americana de Nefrología, centrado en la xantina oxidasa en la enfermedad renal poliquística. El estudio, realizado en la Universidad de Colorado y patrocinado por XORTX, reveló hallazgos significativos tanto en modelos de PKD de ratas como de ratones. Los resultados clave mostraron que el aumento del ácido úrico conducía a un crecimiento mayor de quistes, mientras que el inhibidor de la xantina oxidasa redujo el ácido úrico en suero y el crecimiento de quistes. Los resultados clínicos del Halt Clinical Trial - Grupo A demostraron que los pacientes con ácido úrico en suero elevado experimentaron un aumento en el volumen total del riñón y una progresión más rápida de la PKD. Además, se vinculó un aumento de la actividad de XO sérica con la aparición temprana de hipertensión.
XORTX Therapeutics는 다낭신장병에서의 자안산화효소를 주제로 미국 신장학회에서 그들의 초록이 수용되었다고 발표했습니다. 이 연구는 콜로라도 대학교에서 수행되었고 XORTX의 후원을 받았으며, 쥐와 생쥐의 PKD 모델 모두에서 중요한 결과를 드러냈습니다. 주요 결과는 요산 증가가 낭종 성장을 촉진한다는 것이었고, 자안산화효소 억제제가 혈청 요산과 낭종 성장을 감소시킨다는 것을 보여주었습니다. Halt Clinical Trial - 그룹 A의 임상 결과는 혈청 요산이 증가한 환자들이 신장 총 부피가 증가하고 PKD 진행이 더 빠르다는 것을 입증했습니다. 또한, 혈청 XO 활성이 증가하면 고혈압의 더 빠른 발병과 관련이 있었습니다.
XORTX Therapeutics a annoncé l'acceptation de leur résumé à l'American Society of Nephrology, axé sur l'oxydase de xanthine dans la maladie polykystique des reins. L'étude, menée à l'Université du Colorado et parrainée par XORTX, a révélé des résultats significatifs dans des modèles de PKD chez le rat et la souris. Les résultats clés ont montré qu'une augmentation de l'acide urique entraînait une croissance accrue des kystes, tandis que l'inhibiteur de l'oxydase de xanthine réduisait l'acide urique sérique et la croissance des kystes. Les résultats cliniques de l'essai clinique Halt - Groupe A ont démontré que les patients avec un acide urique sérique élevé présentaient un volume total des reins accru et une progression plus rapide de la PKD. De plus, une activité accrue de XO sérique a été liée à une apparition plus précoce d'hypertension artérielle.
XORTX Therapeutics gab bekannt, dass ihr Abstract bei der American Society of Nephrology akzeptiert wurde, welches sich auf Xanthinoxidase bei der polyzystischen Nierenerkrankung konzentriert. Die Studie, die an der Universität Colorado durchgeführt und von XORTX gesponsert wurde, zeigte signifikante Ergebnisse sowohl in Ratten- als auch in Maus-PKD-Modellen. Die wichtigsten Ergebnisse zeigten, dass ein Anstieg der Harnsäure zu einem erhöhten Zystenwachstum führte, während der Inhibitor der Xanthinoxidase die Serumharnsäure und das Zystenwachstum verringerte. Klinische Ergebnisse aus der Halt Clinical Trial - Gruppe A zeigten, dass Patienten mit erhöhtem Serumharnsäurevolumen ein größeres Gesamtvolumen der Nieren und eine schnellere PKD-Progression aufwiesen. Darüber hinaus wurde eine erhöhte XO-Aktivität im Serum mit einem früheren Auftreten von Bluthochdruck in Verbindung gebracht.
- Study demonstrates positive correlation between uric acid reduction and decreased cyst growth
- Clinical evidence supports company's therapeutic approach in PKD treatment
- Research validates the potential effectiveness of xanthine oxidase inhibitors
- None.
Insights
● Health consequences of chronically high uric acid and xanthine oxidase
in polycystic kidney disease in rats, mice and humans ●
CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology (the “ASN”). The abstract entitled "Xanthine oxidase in rats, mice and humans with polycystic kidney disease" was reviewed by the ASN review panel for scientific merit and novel discoveries. The study was conducted at the University of Colorado in the independent laboratory of Dr. Charles Edelstein and was sponsored by XORTX and will be presented during the Session Title: Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis. Selected results from the study include:
In both Rat or Mouse models of Polycystic Kidney Disease (“PKD”)
i) Use of a uricase inhibitor to increase uric acid resulted in increased cyst growth
ii) Xanthine oxidase (“XO”) inhibitor – Oxypurinol – decreased serum uric acid and cyst growth
iii) Increased XO staining in kidney and liver was abundant
Prospective / Retrospective Clinical Results of the Halt Clinical Trial - Group A - Early PKD patients
iv) Patients with increased serum uric acid had increased total kidney volume
v) Patients with increased serum uric acid had faster PKD progression
vi) Increase serum XO activity was associated with an earlier onset of high blood pressure
About this Study
The XO enzyme is an essential enzyme within the uric acid pathway, and is required for the breakdown of purine nucleotides. Uric acid as well as reactive oxygen species released during the enzymatic reaction may also play a detrimental role in the circulatory system and within tissue during disease. Recent pioneering discoveries in rodent models of PKD implicate over expression or over activity of XO. It is currently unknown if XO over expression or over activity in humans is associated with PKD or more rapid progression of disease. The aim of the study was to gain insight into whether increased XO activity results in cyst growth, XO activity was measured in PCK1 rats, PKD1RC/RC (RC) mice and 34 patients from the HALT-PKD Clinical study.
The abstract outlines study results from rat, mice and human studies of PKD. The purpose of the study was to gain and understanding of serum xanthine oxidase activity (XOa) in PKD during varied stages of disease and further to relate that activity to total kidney volume, and decline of glomerular filtration rate (GFR). The results of the study provide understanding of where aberrant purine metabolism in PKD tissue due to sources XO enzyme may contribute to circulating uric acid levels, expansion rate of kidney and cyst and functional GFR decline. Prior study results suggested over expression of XO in PKD kidney tissue may be a feature of cystic disease.
Dr. Allen Davidoff, CEO of XORTX commented, “Exploring and understanding the contribution of chronically increased serum uric acid and/or the effect of too much or too active XO enzyme in the circulation or tissue on PKD disease progression was a goal of this study. The study results presented today are another pioneering first step towards characterizing how and when to treat individuals with PKD as well as how they might benefit from the Company’s XRx-008 program, and our upcoming registration clinical trial. This study was a preliminary investigation of individuals with early stage PKD, and provided information regarding the health consequences of hyperuricemia and XO. The Company will continue to add to this exciting discovery with future exploration of later stage PKD, assessment of genetic factors contributing to aberrant purine metabolism, including XO overexpression, and this precision medicine opportunity.”
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and health of kidney disease patients. Additional information on XORTX is available at www.xortx.com.
| For more information, please contact: | |
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
FAQ
What were the key findings of XORTX's PKD study presented at ASN Kidney Week 2024?
How did xanthine oxidase inhibitor affect PKD in XRTX's research?
What clinical outcomes were observed in the Halt Clinical Trial for XRTX's PKD research?
